For research use only. Not for therapeutic Use.
Osemitamab (Cat No.: I040852) is a monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed in gastric and pancreatic tumors. By binding to CLDN18.2 on tumor cells, Osemitamab induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), making it a promising agent in cancer immunotherapy. It is especially valuable in gastric cancer research, offering insights into targeted therapies against tumor-specific antigens. Osemitamab supports investigations into precision oncology approaches. For research use only in laboratory and preclinical studies.
| CAS Number | 2460539-61-9 |
| Purity | ≥95% |
| Reference | [1]. Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002)[J]. 2023. [2]. Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
